Xenon Pharmaceuticals (XENE) Stock
Clinical stage biotech developing targeted drugs for brain disorders. Here's the price, business snapshot, and what's worth knowing about Xenon Pharmaceuticals in October 2026.
Xenon Pharmaceuticals Inc (XENE) is a clinical-stage biotechnology company focusing on developing small-molecule therapies for neurological and rare disorders. The company’s research centres on ion-channel biology and precision modulation of neuronal activity, with a pipeline of candidates in various stages of clinical development. With a market capitalisation of about $3.32 billion, Xenon combines laboratory research, clinical trials and regulatory engagement as it seeks to advance programmes toward potential approvals. Investors should note the typical biotech profile: outcomes hinge on trial results, regulatory decisions and successful commercial execution. Clinical progress can drive share price moves, but programmes may also fail or require additional funding. This summary provides general information for educational purposes only and is not personalised investment advice. Consider your risk tolerance and consult a qualified financial adviser before making investment decisions, as biotech stocks can be volatile and carry substantial downside as well as upside potential.
Xenon Pharmaceuticals (XENE) Stock Forecast
Analyst price target, next 12 months
$66.89
+84.2% vs today's $36.32
Price range over the last 12 months
Close to its 12-month low
Analysts covering Xenon Pharmaceuticals have a consensus 12-month target of $66.89, above the current price of $36.32.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 23 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying XENON Pharmaceuticals' stock with a target price of $66.89, indicating strong potential growth.
Financial Health
Xenon Pharmaceuticals is performing well with strong cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline progress to watch
Clinical trial milestones and data releases can materially influence valuation; positive results may lift sentiment, though outcomes are uncertain and can disappoint.
Ion-channel innovation
Xenon’s science centres on ion-channel modulation, a specialised approach that could address unmet needs but also faces scientific and regulatory hurdles.
Regulatory and funding dynamics
Regulatory approvals and financing rounds shape the company’s path to market; investors should be aware of potential dilution and timeline risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
